Recommended Pages at phx.corporate-ir.net
Alnylam Pharmaceuticals - Investor Relations - News Release
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on April 20, 2012 at 12:14 pm By:
New positive Phase I ALN-PCS Clinical results ; reductions of PCSK9 of up to 84% & lowering of LDL-C of up to 50% http://t.co/ff8AVnG6 #ALNY
Alnylam Pharmaceuticals - Investor Relations - News Release
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on March 19, 2012 at 12:11 pm By:
We've advanced ALN-TTR02, #RNAi Tx for treatment of TTR Amyloidosis, to Phase I clinical trial; data expected Q3 2012 http://t.co/dnpWAfwn
Alnylam Pharmaceuticals - Investor Relations - News Release
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on January 11, 2012 at 3:26 pm By:
We’re presenting at JPM this morning 7:30am PT /10:30 am ET listen to webcast: http://t.co/OQsHoV9A #JPM12
Alnylam Pharmaceuticals - Investor Relations - News Release
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on January 4, 2012 at 11:20 am By:
Announcing Ph I data from our ALN-PCS program: safety/tolerability, reduction of up to >50% in volunteers’ LDL levels http://t.co/wGxT2eQM
Error Report
phx.corporate-ir.net — “Error Report” View full resource at phx.corporate-ir.net
Most Recently Shared on December 19, 2011 at 9:21 pm By:
St. Jude Announces First Implant in European Clinical Trial Studying Portico Transcatheter Aortic Valve http://t.co/xlQjZQfq #medicaldevice
Alnylam Pharmaceuticals - Investor Relations - Event Details
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on November 21, 2011 at 11:18 am By:
We’ll b hosting a conference call @8:30AM 2 discuss results of our Phase I ALN-TTR01 clinical trial. Listen to webcast: http://t.co/UHmRjNvy
Alnylam Pharmaceuticals - Investor Relations - News Release
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on November 18, 2011 at 10:03 pm By:
We’re presenting new Ph I data from our ALN-TTR program next wk. Conference call & webcast to be held @ 8:30am, 11/21: http://t.co/mb0yOz7K
Alnylam Pharmaceuticals - Investor Relations - News Release
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on November 1, 2011 at 12:51 pm By:
We formed a collab w/ GSK using our VaxiRNA platform - a new application of RNAi tech to enhance vaccine production. http://t.co/tUyQBOSh
Wright Medical Technology | Investor Relations | News Release
phx.corporate-ir.net — “Wright Medical Technology | Investor Relations | News Release” View full resource at phx.corporate-ir.net
Most Recently Shared on September 19, 2011 at 2:01 pm By:
Dr Thomas H. Lee Active Health Library, Doctor, Surgeon, Orthopedic Surgeon, and Physician
A new CEO at Wright Medical. http://t.co/0ncL4pG1
Alnylam Pharmaceuticals - Investor Relations - Event Details
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on September 14, 2011 at 12:41 pm By:
Our CEO will be "unplugged" at Morgan Stanley today at 10:55am. Listen to the webcast http://t.co/IYNPEg5 #Alnylam #RNAiTx
Affymetrix - About Affymetrix - Investors - Press Release
phx.corporate-ir.net — “Affymetrix is dedicated to developing state-of-the-art technology for acquiring, analyzing, and managing complex genetic information for use in biomedical research. Affymetrix sells GeneChip® brand microarrays.” View full resource at phx.corporate-ir.net
Most Recently Shared on September 9, 2011 at 2:06 pm By:
Walter Jessen, PhD Pharma, Research, PhD, Active Health Library, and Doctor
Affymetrix recently announced the Human Transcriptome and Splice Junction Array, outperforms RNA-Seq http://ow.ly/6pQTy #ADAPT2011 #bdi
Alnylam Pharmaceuticals - Investor Relations - Event Details
phx.corporate-ir.net — “Alnylam Pharmceuticals - Investor Relations” View full resource at phx.corporate-ir.net
Most Recently Shared on September 8, 2011 at 12:34 am By:
Our President & COO, Barry Greene, will be presenting @ Stifel Nicolaus Healthcare 9/8, 10:55AM ET. Webcast: http://t.co/nEXRVkm #ALNY
News Release - Investors - Protalix Biotherapeutics
phx.corporate-ir.net — “News Release - Investors - Protalix Biotherapeutics” View full resource at phx.corporate-ir.net
Most Recently Shared on August 17, 2011 at 1:17 pm By:
eyeonfda Pharma and Health Lawyer
Protalix BioTherapeutics Says #FDA Accepts 4 Review CRL Resubmission 4 Taliglucerase Alfa; Assigns PDUFA Date http://ow.ly/65mEi #Gaucher
Alkermes - RSS Content
phx.corporate-ir.net — “Alkermes - RSS Content” View full resource at phx.corporate-ir.net
Most Recently Shared on August 11, 2011 at 1:15 pm By:
eyeonfda Pharma and Health Lawyer
BYDUREON™ resubmission - FDA Action Date Set For January 28, 2012 - http://ow.ly/60Duh #diabetes
HCA Healthcare | Investor Relations | News
phx.corporate-ir.net — “HCA Healthcare | Investor Relations | News” View full resource at phx.corporate-ir.net
Most Recently Shared on August 10, 2011 at 4:34 pm By:
Healthcare Marketing Health Social Media
@hcahealthcare Named to Hospitals & Health Networks' Most Wired List http://bit.ly/odYZxb #hcmktg #hchit #mhealth
